Calculate your SIP ReturnsExplore

Caplin Steriles Receives USFDA Nod for Ephedrine Sulfate Injection

19 July 20243 mins read by Angel One
Caplin Steriles gets US FDA approval for Ephedrine Sulfate Injection USP, which will help Caplin expand its business in the USA.
Caplin Steriles Receives USFDA Nod for Ephedrine Sulfate Injection
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Caplin Steriles Limited (Caplin), a subsidiary of Caplin Point Laboratories Limited, has secured significant approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ephedrine Sulfate Injection USP, 50 mg/mL Single Dose Vial. This generic version is therapeutically equivalent to the reference-listed drug (RLD) AKOVAZ, manufactured by Exela Pharma Sciences LLC.

Expanding Product Portfolio

This USFDA approval marks another milestone for Caplin Steriles’ growing portfolio of injectable and ophthalmic products targeting the lucrative US market. The approved Ephedrine Sulfate injection is indicated for treating clinically important hypotension (low blood pressure) occurring during anaesthesia.

Market Potential

According to IQVIA™ (IMS Health), Ephedrine Sulfate injection USP 50 mg/mL holds substantial market potential in the US, with estimated sales of approximately $36 million for the twelve months ending May 2024. By entering this market with a generic alternative, Caplin Steriles is well-positioned to capture a significant share and contribute to cost-effective treatment options for patients.

Building on Previous Success

This recent approval follows Caplin Steriles’ successful USFDA nod in May 2024 for their Abbreviated New Drug Application (ANDA) for Phenylephrine Hydrochloride Ophthalmic Solution USP 2.5% and 10% (eye drops). This generic equivalent of the RLD from Alcon Research LLC is used for pupil dilation during eye examinations.

Strategic Focus on the US Market

Caplin Steriles’ continued focus on obtaining US FDA approvals for its generic injectable and ophthalmic products demonstrates its strategic commitment to expanding its presence in the world’s largest pharmaceutical market. These approvals not only represent significant revenue opportunities but also showcase Caplin Steriles’ robust capabilities in developing high-quality, US-market-compliant products.

About Caplin Steriles Limited

Caplin Steriles Limited, a Subsidiary of Caplin Point Laboratories Limited, is a fast growing sterile product manufacturing company that is approved by several regulatory agencies such as US FDA, EU-GMP, ANVISA and INVIMA.

About Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model that caters predominantly to emerging markets in Latin America and Africa.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.

Open Free Demat Account!

Enjoy Zero Brokerage on Equity Delivery

Join our 2 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy Zero Brokerage on Equity Delivery

Get the link to download the App

Send App Link
Open Free Demat Account!
Enjoy Zero Brokerage on Stock Investments.